Relationship between Functional Disability and Bone Loss in Spondyloartropathy Patients

Abstract

Objective: To determine the relationship between bone mineral density (BMD) and functional status of spondyloarthropathy (SpA) patients. Methods: BMD (g/cm 2) of 139 SpA patients was determined at the lumbar spine and the upper part of the left and right femur by dual energy X-ray absorptiometry (DXA). The functional disability in patients with SpA was assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Patient Global Assessment (BAS-G), the Health Assessment Questionnaire Modified for the SpA (HAQ-S); spinal mobility - by measuring metrology indices (tragus-to wall distance, lateral flexion, modified Schober’s distance, and intermalleolar distance). Physical activity was measured by amount of time spent exercising per week. In order to find out whether there was a relationship between functional indices and BMD linear regression stepwise selection was employed. Results: No significant association between frequency of exercise and BMD was detected in SpA patients. Femur BMD was associated with BASFI, HAQ-S and all components of metrology indices, except for tragus to wall distance for left femur. Significant decreases of right and left femur BMD, except for the spine BMD, were associated with cases of severe impairment of lumbar side flexion, and impairment of modified Schober’s test and intermalleolar distance. Spinal BMD was associated only with HAQ-S.Conclusions: Femur BMD of SpA patients was found to be associated with both subjective (BASFI, HAQ-S) and objective (tragus to wall distance, lumbar side flexion, modified Schober’s test and intermalleolar distance) functional indices. Prevention of bone loss of SpA patients relies upon preservation and control of functional status of the patient

Keywords

• Functional Disability, Bone Mineral Density, Spondyloarthropathies.

Relationship between Functional Disability and Bone Loss in Spondyloartropathy Patients

Abstract

References

1. Ward MM: Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. 12: 247-55, 1999.
2. Guillemin F, Briancion S, Pourel J, Gaucher A: Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis: possible predictive factors. Arthritis Rheum. 33: 1001-6, 1990.
3. Gran JT, Skomsvoll JF: The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol. 36: 766-71, 1997.
4. Taylor AL, Balakrishnan C, Calin AL: Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum. 41: 25, 1998.
5. Zink A, Braun J, Listing J, Wollenhaupt J, and the German Collaborative Arthritis Centers. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: results from the German rheumatological database. 27: 613-22, Falkenbach A, Franke A, van Tubergen A, van der Linden S: Assessment of functional ability in younger and older patients with ankylosing spondylitis: performance of the Bath Ankylosing Spondylitis Functional Index. Am J Phys Med Rehabil. 81: 416-20, 2002.
6. Falkenbach A, Franke A, van der Linden S: Factors associated with body function and disability in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol. 30: 2186- , 2003.
7. Ward MM: Predictors of the progression pf functional disability in patients with ankylosing spondylitis. J Rheumatol. 29: 1420-5, 2002.
8. Doran MF, Brophy S, MacKay K, Taylor G, Calin A: Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol. 30: 316-20, Wordsworth BP, Mowat AG: A review of patients with ankylosing spondylitis with particular reference to socio-economic effects. Br J Rheumatol. 25: 175-80, 1986.

9. Bakker C, van de Linden S, van Santen- Hoeufft M, Bolwijn P, Hidding A: Problem elicitations to assess patient priorities in ankylosing spondylitis and fibromyalgia. J Rheumatol. 22: 1304-10, 1995.
10. Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT: Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol. 25: 138-42, 1996.
11. Heikkila S, Ronni S, Kautiainen H.J, Kauppi M.J: spondyloarthropathy Rheumatol 29: 1415-9, 2002. van der Heijde D, Calin A, Dougados M
12. Khan M, van der Linden S, Bellamy N: Selection of instruments in the core set for DC- ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working group. J Rheumatol. 26: 951-4, 1999.
13. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T: A new approach to defining functional ability in anklosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 21: 2281-5, 1994.
14. Daltroy LH, Larson MG, Roberts WN, Liang MH: A modification of the Health Assessment spondyloarthropathies. J Rheumatol. 17: 946-50, Jones SD, Steiner A, Garrett SL, Calin A: The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol. 35: 66-71, Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A: Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 21: 1698, 1994.
15. Meirelles ES, Borelli A, Camargo OP: Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol. 18: 364-8, 1999.
16. El Maghraoul A, Borderie D, Cherruau B, Edouard R, Dougados M, Roux C: Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol. 26: 2205-9
17. Venceviciene L, Venalis A, Sapoka V, Butrimiene I: Bone mineral density in patients with spondyloarthropathies. Medicinos teorija ir praktika. 14(3): 275-282, 2008.
18. Deodhar AA, Woolf AD: Bone mass measurement impairment in J and fibromyalgia. Questionnaire for and bone metabolism in rheumatoid arthritis: a review. British Journal of Reumatology. 35: 309-22, 1996.
19. Kanis JA: Osteoporosis. Victoria, Blackwell Science Ltd. Pp. 1-254, 1994.
20. Nishimura J, Ikuyama S: Glucocorticoid- induced osteoporosis: pathogenesis and management. Journal of Bone and Mineral Metabolism. 18: 350-2, 2000.
21. Bonnick SL, Johnston CC Jr, Kleerekoper M, Lindsay R, Miller P, Sherwood L, Siris E: Importance of precision in bone density measurements. J Clin Densitom. 4: 105, 2001.
22. Illei GG, Lipsky PE: Novel, non-antigen- specific autoimmune/inflammatory diseases. Curr Opin Immunol. 12: 712-718, 2000. Rehman Q, approaches for preventing inflammatory bone loss in inflammatory arthritis. Arthritis Res. 3: 227, 2001.
23. Venceviciene L, Venalis A, Butrimiene I: Loss of bone mass: when it begins in immune arthritides. Gerontologija. 9(2): 71-78, 2008.
24. Will R, Bhalla AK, Palmer R, Ring R, Calin A: Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet. II: 1483– , 1989.
25. Mitra D, Elvins DM, Speden DJ, Collins AJ: The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology. 39: 85-89, Bikle DD, Halloran BP: The response of bone to unloading. J Bone Miner Metab. 17: 44, 1999.
26. Mullaji AB, Upadhyay SS, Ho EKW: Bone mineral density in ankylosing spondylitis: DEXA comparison of control subjects with mild and advanced cases. J Bone Joint Surg Br. 76: 5, 1994.
27. Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C: Changes in bone density in patients with ankylosing spondylitis: a two- year follow up study. Osteoporos Int. 12: 605–9, Gratacos J, Collado A, Pons F, Osaba M, Sanmarti R, Roque M, Larrosa M, Munoz- Gomez J: Significant loss of bone mass in patients spondylitis. J Rheumatol. 41: 2319-2324, 1999. active ankylosing absorptiometry and with